# Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

> **NCT07743632** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 110 (estimated)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT07743632
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2032-12
- **Final completion:** 2033-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743632, "Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*